

EUROPEAN PATENT OFFICE
U.S. PATENT AND TRADEMARK OFFICE

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

The following classification changes will be effected by this Notice of Changes:

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
Symbols newly created:	A61P	subclass
		A61P 1/00
		A61P 1/02
		A61P 1/04
		A61P 1/06
		A61P 1/08
		A61P 1/10
		A61P 1/12
		A61P 1/14
		A61P 1/16
		A61P 1/18
		A61P 3/00
		A61P 3/02
		A61P 3/04
		A61P 3/06
		A61P 3/08
		A61P 3/10
		A61P 3/12
		A61P 3/14
		A61P 5/00
		A61P 5/02
		A61P 5/04
		A61P 5/06
		A61P 5/08
		A61P 5/10
		A61P 5/12
		A61P 5/14
		A61P 5/16
		A61P 5/18
		A61P 5/20
		A61P 5/22
		A61P 5/24
		A61P 5/26
		A61P 5/28
		A61P 5/30
		A61P 5/32
		A61P 5/34
		A61P 5/36
		A61P 5/38
		A61P 5/40
		A61P 5/42

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
		A61P 5/44
		A61P 5/46
		A61P 5/48
		A61P 5/50
		A61P 7/00
		A61P 7/02
		A61P 7/04
		A61P 7/06
		A61P 7/08
		A61P 7/10
		A61P 7/12
		A61P 9/00
		A61P 9/02
		A61P 9/04
		A61P 9/06
		A61P 9/08
		A61P 9/10
		A61P 9/12
		A61P 9/14
		A61P 11/00
		A61P 11/02
		A61P 11/04
		A61P 11/06
		A61P 11/08
		A61P 11/10
		A61P 11/12
		A61P 11/14
		A61P 11/16
		A61P 13/00
		A61P 13/02
		A61P 13/04
		A61P 13/06
		A61P 13/08
		A61P 13/10
		A61P 13/12
		A61P 15/00
		A61P 15/02
		A61P 15/04
		A61P 15/06
		A61P 15/08
		A61P 15/10
		A61P 15/12
		A61P 15/14
		A61P 15/16

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
		A61P 15/18
		A61P 17/00
		A61P 17/02
		A61P 17/04
		A61P 17/06
		A61P 17/08
		A61P 17/10
		A61P 17/12
		A61P 17/14
		A61P 17/16
		A61P 17/18
		A61P 19/00
		A61P 19/02
		A61P 19/04
		A61P 19/06
		A61P 19/08
		A61P 19/10
		A61P 21/00
		A61P 21/02
		A61P 21/04
		A61P 21/06
		A61P 23/00
		A61P 23/02
		A61P 25/00
		A61P 25/02
		A61P 25/04
		A61P 25/06
		A61P 25/08
		A61P 25/10
		A61P 25/12
		A61P 25/14
		A61P 25/16
		A61P 25/18
		A61P 25/20
		A61P 25/22
		A61P 25/24
		A61P 25/26
		A61P 25/28
		A61P 25/30
		A61P 25/32
		A61P 25/34
		A61P 25/36
		A61P 27/00

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
		A61P 27/02
		A61P 27/04
		A61P 27/06
		A61P 27/08
		A61P 27/10
		A61P 27/12
		A61P 27/14
		A61P 27/16
		A61P 29/00
		A61P 29/02
		A61P 31/00
		A61P 31/02
		A61P 31/04
		A61P 31/06
		A61P 31/08
		A61P 31/10
		A61P 31/12
		A61P 31/14
		A61P 31/16
		A61P 31/18
		A61P 31/20
		A61P 31/22
		A61P 33/00
		A61P 33/02
		A61P 33/04
		A61P 33/06
		A61P 33/08
		A61P 33/10
		A61P 33/12
		A61P 33/14
		A61P 35/00
		A61P 35/02
		A61P 35/04
		A61P 37/00
		A61P 37/02
		A61P 37/04
		A61P 37/06
		A61P 37/08
		A61P 39/00
		A61P 39/02
		A61P 39/04
		A61P 39/06

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
		A61P 41/00
		A61P 43/00
Scheme Notes to be added:	A61P	subclass
		A61P 43/00
	A61Q	subclass
	C40B	subclass
New Definitions:	A61P	subclass
	A61P	1/00
		3/00
		5/00
		7/00
		9/00
		11/00
		13/00
		15/00
		17/00
		19/00
		21/00
		23/00
		25/00
		27/00
		29/00
		31/00
		33/00
		35/00
		37/00
		39/00
		41/00
		43/00
Definitions Quick fix	A61K	31/00
		35/00
		48/00
	A61Q	subclass
	C07C	subclass
	C07D	subclass
	C07H	subclass
	C07J	subclass

The following subclasses/groups are also impacted by this Notice of Changes:
A61N, C01B, C08F, C08G, C08H, C08L, C12N

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

This Notice of Changes includes the following *[Check the ones included]:*

1. CLASSIFICATION SCHEME CHANGES
 - A. New, Modified or Deleted Group(s)
 - B. New, Modified or Deleted Warning Notice(s)
 - C. New, Modified or Deleted Note(s)
 - D. New, Modified or Deleted Guidance Heading(s)
2. DEFINITIONS (New or Modified)
 - A. DEFINITIONS (Full definition template)
 - B. DEFINITIONS (Definitions Quick Fix)
3. REVISION CONCORDANCE LIST (RCL)
4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)
5. CROSS-REFERENCE LIST (CRL)

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

1. CLASSIFICATION SCHEME CHANGES

A. New, Modified or Deleted Group(s)**SUBCLASS A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS**

<u>Type*</u>	<u>Symbol</u>	<u>Indent Level Number of dots (e.g. 0, 1, 2)</u>	<u>Title (new or modified)</u> <u>“CPC only” text should normally be enclosed in {curly brackets}**</u>	<u>Transferred to[#]</u>
N	A61P	Subclass	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS	
N	A61P 1/00	0	Drugs for disorders of the alimentary tract or the digestive system	
N	A61P 1/02	1	Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis	
N	A61P 1/04	1	for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants	
N	A61P 1/06	1	Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia	
N	A61P 1/08	1	for nausea, cinetosis or vertigo; Antiemetics	
N	A61P 1/10	1	Laxatives	
N	A61P 1/12	1	Antidiarrhoeals	
N	A61P 1/14	1	Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents	
N	A61P 1/16	1	for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics	
N	A61P 1/18	1	for pancreatic disorders, e.g. pancreatic enzymes	
N	A61P 3/00	0	Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00)	
N	A61P 3/02	1	Nutrients, e.g. vitamins, minerals	
N	A61P 3/04	1	Anorexiant; Antiobesity agents	
N	A61P 3/06	1	Antihyperlipidemics	
N	A61P 3/08	1	for glucose homeostasis (pancreatic hormones A61P 5/48)	
N	A61P 3/10	2	for hyperglycaemia, e.g. antidiabetics	
N	A61P 3/12	1	for electrolyte homeostasis	
N	A61P 3/14	2	for calcium homeostasis (vitamin D A61P 3/02; parathyroid hormones A61P 5/18; calcitonin A61P 5/22; osteoporosis A61P 19/10; bone metastasis A61P 35/04)	
N	A61P 5/00	0	Drugs for disorders of the endocrine system	
N	A61P 5/02	1	of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin	

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61P 5/04	2	for decreasing, blocking or antagonising the activity of the hypothalamic hormones	
N	A61P 5/06	1	of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH	
N	A61P 5/08	2	for decreasing, blocking or antagonising the activity of the anterior pituitary hormones	
N	A61P 5/10	1	of the posterior pituitary hormones, e.g. oxytocin, ADH	
N	A61P 5/12	2	for decreasing, blocking or antagonising the activity of the posterior pituitary hormones	
N	A61P 5/14	1	of the thyroid hormones, e.g. T3, T4	
N	A61P 5/16	2	for decreasing, blocking or antagonising the activity of the thyroid hormones	
N	A61P 5/18	1	of the parathyroid hormones	
N	A61P 5/20	2	for decreasing, blocking or antagonising the activity of PTH	
N	A61P 5/22	2	for decreasing, blocking or antagonising the activity of calcitonin	
N	A61P 5/24	1	of the sex hormones	
N	A61P 5/26	2	Androgens	
N	A61P 5/28	2	Antiandrogens	
N	A61P 5/30	2	Oestrogens	
N	A61P 5/32	2	Antioestrogens	
N	A61P 5/34	2	Gestagens	
N	A61P 5/36	2	Antigestagens	
N	A61P 5/38	1	of the suprarenal hormones	
N	A61P 5/40	2	Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids	
N	A61P 5/42	2	for decreasing, blocking or antagonising the activity of mineralocorticosteroids	
N	A61P 5/44	2	Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids	
N	A61P 5/46	2	for decreasing, blocking or antagonising the activity of glucocorticosteroids	
N	A61P 5/48	1	of the pancreatic hormones	
N	A61P 5/50	2	for increasing or potentiating the activity of insulin	
N	A61P 7/00	0	Drugs for disorders of the blood or the extracellular fluid	
N	A61P 7/02	1	Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors	
N	A61P 7/04	1	Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents	
N	A61P 7/06	1	Antianaemics	
N	A61P 7/08	1	Plasma substitutes; Perfusion solutions; Dialytics or	

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
			haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04)	
N	A61P 7/10	1	Antioedematous agents; Diuretics	
N	A61P 7/12	1	Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10)	
N	A61P 9/00	0	Drugs for disorders of the cardiovascular system	
N	A61P 9/02	1	Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives	
N	A61P 9/04	1	Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure	
N	A61P 9/06	1	Antiarrhythmics	
N	A61P 9/08	1	Vasodilators for multiple indications	
N	A61P 9/10	1	for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis	
N	A61P 9/12	1	Antihypertensives	
N	A61P 9/14	1	Vasoprotectives; Antihæmorrhoidals; Drugs for varicose therapy; Capillary stabilisers	
N	A61P 11/00	0	Drugs for disorders of the respiratory system	
N	A61P 11/02	1	Nasal agents, e.g. decongestants	
N	A61P 11/04	1	for throat disorders	
N	A61P 11/06	1	Antiasthmatics	
N	A61P 11/08	1	Bronchodilators	
N	A61P 11/10	1	Expectorants	
N	A61P 11/12	1	Mucolytics	
N	A61P 11/14	1	Antitussive agents	
N	A61P 11/16	1	Central respiratory analeptics	
N	A61P 13/00	0	Drugs for disorders of the urinary system	
N	A61P 13/02	1	of urine or of the urinary tract, e.g. urine acidifiers	
N	A61P 13/04	1	for urolithiasis	
N	A61P 13/06	1	Anti-spasmodics	
N	A61P 13/08	1	of the prostate	
N	A61P 13/10	1	of the bladder	
N	A61P 13/12	1	of the kidneys	
N	A61P 15/00	0	Drugs for genital or sexual disorders (for disorders of sex hormones A61P 5/24); Contraceptives	
N	A61P 15/02	1	for disorders of the vagina	
N	A61P 15/04	1	for inducing labour or abortion; Uterotonics	
N	A61P 15/06	1	Antiabortive agents; Labour repressants	
N	A61P 15/08	1	for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis	
N	A61P 15/10	1	for impotence	
N	A61P 15/12	1	for climacteric disorders	
N	A61P 15/14	1	for lactation disorders, e.g. galactorrhoea	

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61P 15/16	1	Masculine contraceptives	
N	A61P 15/18	1	Feminine contraceptives	
N	A61P 17/00	0	Drugs for dermatological disorders	
N	A61P 17/02	1	for treating wounds, ulcers, burns, scars, keloids, or the like	
N	A61P 17/04	1	Antipruritics	
N	A61P 17/06	1	Antipsoriatics	
N	A61P 17/08	1	Antiseborrheics	
N	A61P 17/10	1	Anti-acne agents	
N	A61P 17/12	1	Keratolytics, e.g. wart or anti-corn preparations	
N	A61P 17/14	1	for baldness or alopecia	
N	A61P 17/16	1	Emollients or protectives, e.g. against radiation	
N	A61P 17/18	1	Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00)	
N	A61P 19/00	0	Drugs for skeletal disorders	
N	A61P 19/02	1	for joint disorders, e.g. arthritis, arthrosis	
N	A61P 19/04	1	for non-specific disorders of the connective tissue	
N	A61P 19/06	1	Antigout agents, e.g. antihyperuricemic or uricosuric agents	
N	A61P 19/08	1	for bone diseases, e.g. rachitism, Paget's disease	
N	A61P 19/10	2	for osteoporosis	
N	A61P 21/00	0	Drugs for disorders of the muscular or neuromuscular system	
N	A61P 21/02	1	Muscle relaxants, e.g. for tetanus or cramps	
N	A61P 21/04	1	for myasthenia gravis	
N	A61P 21/06	1	Anabolic agents (androgens A61P 5/26)	
N	A61P 23/00	0	Anaesthetics	
N	A61P 23/02	1	Local anaesthetics	
N	A61P 25/00	0	Drugs for disorders of the nervous system	
N	A61P 25/02	1	for peripheral neuropathies	
N	A61P 25/04	1	Centrally acting analgesics, e.g. opioids	
N	A61P 25/06	1	Antimigraine agents	
N	A61P 25/08	1	Antiepileptics; Anticonvulsants	
N	A61P 25/10	2	for petit-mal	
N	A61P 25/12	2	for grand-mal	
N	A61P 25/14	1	for treating abnormal movements, e.g. chorea, dyskinesia	
N	A61P 25/16	2	Anti-Parkinson drugs	
N	A61P 25/18	1	Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia	
N	A61P 25/20	1	Hypnotics; Sedatives	
N	A61P 25/22	1	Anxiolytics	
N	A61P 25/24	1	Antidepressants	
N	A61P 25/26	1	Psychostimulants, e.g. nicotine, cocaine	

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61P 25/28	1	for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia	
N	A61P 25/30	1	for treating abuse or dependence	
N	A61P 25/32	2	Alcohol-abuse	
N	A61P 25/34	2	Tobacco-abuse	
N	A61P 25/36	2	Opioid-abuse	
N	A61P 27/00	0	Drugs for disorders of the senses	
N	A61P 27/02	1	Ophthalmic agents	
N	A61P 27/04	2	Artificial tears; Irrigation solutions	
N	A61P 27/06	2	Antiglaucoma agents or miotics	
N	A61P 27/08	2	Mydriatics or cycloplegics	
N	A61P 27/10	2	for accommodation disorders, e.g. myopia	
N	A61P 27/12	2	for cataracts	
N	A61P 27/14	2	Decongestants or antiallergics	
N	A61P 27/16	1	Otologicals	
N	A61P 29/00	0	Non-central analgesic, antipyretic or anti-inflammatory agents, e.g. antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)	
N	A61P 29/02	1	without antiinflammatory effect	
N	A61P 31/00	0	Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics	
N	A61P 31/02	1	Local antiseptics	
N	A61P 31/04	1	Antibacterial agents	
N	A61P 31/06	2	for tuberculosis	
N	A61P 31/08	2	for leprosy	
N	A61P 31/10	1	Antimycotics	
N	A61P 31/12	1	Antivirals	
N	A61P 31/14	2	for RNA viruses	
N	A61P 31/16	3	for influenza or rhinoviruses	
N	A61P 31/18	3	for HIV	
N	A61P 31/20	2	for DNA viruses	
N	A61P 31/22	3	for herpes viruses	
N	A61P 33/00	0	Antiparasitic agents	
N	A61P 33/02	1	Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis	
N	A61P 33/04	2	Amoebicides	
N	A61P 33/06	2	Antimalarials	
N	A61P 33/08	2	for Pneumocystis carinii	
N	A61P 33/10	1	Anthelmintics	
N	A61P 33/12	2	Schistosomicides	
N	A61P 33/14	1	Ectoparasiticides, e.g. scabicides	
N	A61P 35/00	0	Antineoplastic agents	

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61P 35/02	1	specific for leukemia	
N	A61P 35/04	1	specific for metastasis	
N	A61P 37/00	0	Drugs for immunological or allergic disorders	
N	A61P 37/02	1	Immunomodulators	
N	A61P 37/04	2	Immunostimulants	
N	A61P 37/06	2	Immunosuppressants, e.g. drugs for graft rejection	
N	A61P 37/08	1	Antiallergic agents (antiasthmatic agents A61P 11/06; ophthalmic antiallergics A61P 27/14)	
N	A61P 39/00	0	General protective or antinoxious agents	
N	A61P 39/02	1	Antidotes	
N	A61P 39/04	1	Chelating agents	
N	A61P 39/06	1	Free radical scavengers or antioxidants	
N	A61P 41/00	0	Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution	
N	A61P 43/00	0	Drugs for specific purposes, not provided for in groups A61P 1/00-A61P 41/00	

*N = new entries where reclassification into entries is involved; C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; E= existing entries with enlarged file scope, which receive documents from C or D entries, e.g. when a limiting reference is removed from the entry title; M = entries with no change to the file scope (no reclassification); D = deleted entries; F = frozen entries will be deleted once reclassification of documents from the entries is completed; U = entries that are unchanged.

NOTES:

- **No {curly brackets} are used for titles in CPC only subclasses, e.g. C12Y, A23Y; 2000 series symbol titles of groups found at the end of schemes (orthogonal codes); or the Y section titles. The {curly brackets} are used for 2000 series symbol titles found interspersed throughout the main trunk schemes (breakdown codes).
- For U groups, the minimum requirement is to include the U group located immediately prior to the N group or N group array, in order to show the N group hierarchy and improve the readability and understanding of the scheme. Always include the symbol, indent level and title of the U group in the table above.
- All entry types should be included in the scheme changes table above for better understanding of the overall scheme change picture. Symbol, indent level, and title are required for all types except "D" which requires only a symbol.
- #“Transferred to” column must be completed for all C, D, F, and Q type entries. F groups will be deleted once reclassification is completed.
- When multiple symbols are included in the “Transferred to” column, avoid using ranges of symbols in order to be as precise as possible.
- For administrative transfer of documents, the following text should be used: “< administrative transfer to XX>” or “<administrative transfer to XX and YY simultaneously>” when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be “invention information”, unless otherwise indicated, and to 2000 series groups is assumed to be “additional information”.

DATE: JANUARY 1, 2018

PROJECT RP0329

B. New, Modified or Deleted Note(s)**SUBCLASS A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS**

<u>Type*</u>	<u>Location</u>	<u>Old Note</u>	<u>New/Modified Note</u>
N	A61P subclass		<p><u>NOTES</u></p> <ol style="list-style-type: none"> 1. This subclass <u>covers</u> therapeutic activity of chemical compounds or medicinal preparations already classified as such in subclasses A61K or C12N, or in classes C01, C07 or C08. 2. In this subclass, the term "drugs" includes chemical compounds or compositions with therapeutic activity. 3. In this subclass, therapeutic activity is classified in all appropriate places {to the extent of all the different therapeutic activities stated in the claims and also significantly disclosed as examples in the disclosure}. 4. Attention is drawn to cases where the subject of the invention concerns only specific therapeutic activity of chemical compounds or medical preparations, and the chemical structure, compound, mixture or composition of this subject of the invention is known. In such cases, classification is made in both subclass A61K and subclass A61P as invention information. In addition, if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is considered to represent information of interest for search, it may also be classified as additional information. {There is no classification in C01, C07, C08, C12N as additional information in CPC if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is known and classification is made in both subclass A61K and subclass A61P as invention information.} 5. The classification symbols of this subclass are not listed first when assigned to patent documents.
N	A61P 43/00		<p><u>NOTES</u></p> <p>Classification is only made in this group when a specific therapeutic activity for a chemical compound or medicinal preparation has been clearly disclosed, the specific therapeutic activity not being appropriate to any of groups A61P 1/00 - A61P 41/00.</p>

*N = new note, M = modified note, D = deleted note

CPC Form - v.4

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

NOTE: The "Location" column only requires the symbol PRIOR to the location of the note. No further directions such as "before" or "after" are required.

A61Q - SPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS

Type*	Location	<u>Old Note</u>	<u>New/Modified Note</u>
M	A61Q	NOTES 2. Since subclass A61P is not activated in ECLA, relevant IPC Note (2) is not applicable.	2. When classifying this subclass, subclass A61P {is for secondary classification and} covers therapeutic activity of chemical compounds or medicinal preparations.

*N = new note, M = modified note, D = deleted note

NOTE: The "Location" column only requires the symbol PRIOR to the location of the note. No further directions such as "before" or "after" are required.

C40B - COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES

Type*	Location	<u>Old Note</u>	<u>New/Modified Note</u>
M	C40B (2. Note)	A61P Therapeutic activity of compounds	A61P Specific therapeutic activity of chemical compounds or medicinal preparations

*N = new note, M = modified note, D = deleted note

NOTE: The "Location" column only requires the symbol PRIOR to the location of the note. No further directions such as "before" or "after" are required.

DATE: JANUARY 1, 2018

PROJECT RP0329

2. A. DEFINITIONS (new)

Insert the following new definitions.

A61P

Definition statement

This place covers:

Therapeutic activity of chemical compounds or medicinal preparations.

Relationships with other classification places

For medicinal, dental or cosmetic preparations to be appropriate for this subclass, it must also be appropriate for one of the following: subclasses [A61K](#) or [C12N](#), or classes [C01](#), [C07](#), and [C08](#).

[A61Q](#) covers the specific use of cosmetic or similar toilet preparations that are already classified as such in main group [A61K 8/00](#).

There is no classification in [C01](#), [C07](#), [C08](#), and [C12N](#) as additional information in CPC if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is known and classification is made in both subclass [A61K](#) and subclass [A61P](#) as invention information.

References

Informative references

Attention is drawn to the following places, which may be of interest for search:

Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings	A61Q 17/00
--	----------------------------

DATE: JANUARY 1, 2018

PROJECT RP0329

Special rules of classification

In this subclass, all of the different therapeutic activities stated in the claims and also significantly disclosed as examples in the disclosure are classified in all appropriate places.

The classification symbols of this subclass are not listed first when assigned to patent documents.

Glossary of terms

In this place, the following terms (or expressions) are used with the meaning indicated:

Drug(s)	Includes chemical compounds or compositions with therapeutic activity, i.e. having the ability to cause a physiological, pharmacological or biological effect.
---------	--

A61P 1/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the alimentary tract or the digestive system.

A61P 3/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat metabolic disorders.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 5/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the endocrine system.

A61P 7/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the blood or the extracellular fluid.

A61P 9/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the cardiovascular system.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 11/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the respiratory system.

A61P 13/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the urinary system.

A61P 15/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat genital or sexual disorders. This group also covers contraceptives.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 17/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat dermatological disorders.

A61P 19/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat skeletal disorders.

A61P 21/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the muscular or neuromuscular system.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 23/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having anaesthetic activity.

A61P 25/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the nervous system.

A61P 27/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat disorders of the senses.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 29/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having non-central analgesic, antipyretic, anti-inflammatory, or antirheumatic activity. This group also includes non-steroidal anti-inflammatory drugs (NSAIDS)

A61P 31/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is anti-infective, antibiotic, or antiseptic. This group also covers chemotherapeutics.

A61P 33/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having antiparasitic activity.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 35/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having antineoplastic activity.

A61P 37/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used to treat immunological or allergic disorders.

A61P 39/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having general protective or antinoxious activity.

DATE: JANUARY 1, 2018

PROJECT RP0329

A61P 41/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity wherein such activity is used in surgical processes.

A61P 43/00

Definition statement

This place covers:

Drugs, including chemical compounds, compositions, or medicinal preparations having therapeutic activity or purpose not provided for in groups [A61P 1/00](#) - [A61P 41/00](#).

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

2. B. DEFINITIONS QUICK FIX

<u>Symbol</u>	<u>Location of change</u> (e.g., section title)	<u>Existing reference symbol or text</u>	<u>Action; New symbol; New text</u>
A61K31/00	Relationships with other classification places	7 th paragraph: Contrary to IPC, no symbols exist in CPC for classifying the specific therapeutic effect (diseases and pathological conditions) claimed.	<u>Delete</u> entire paragraph
A61K35/00	Informative references		<u>Insert</u> the following <u>new</u> row in the Informative references table: Therapeutic activity of chemical compounds A61P
A61K48/00	Informative references	Specific therapeutic activities A61P (IPC)	<u>Replace</u> the existing symbol designation (A61P IPC) with the following symbol: A61P
A61Q subclass	Relationship with other classification places	Compositions which can be used in a therapeutic treatment should be further classified in A61K 31/00 to A61K 51/00 if they are defined by their ingredients or in A61K 9/00, if they are defined by their physical form, and also in A61P (IPC).	<u>Replace</u> with the following text: Compositions which can be used in a therapeutic treatment should be further classified in A61P and also in A61K 31/00 - A61K 51/00 if they are defined by their ingredients or in A61K 9/00 if they are defined by their physical form.
A61Q subclass	Limiting references	Therapeutic activity A61P17/00	<u>Delete</u> the entire row
C07C subclass	Relationships with other classification places	A non-exhaustive list of other places frequently encountered in association with compounds or processes classified in C07C is included in the Informative References below.	<u>Insert</u> below the existing text (paragraph) the following <u>new</u> paragraph: “Therapeutic activity of chemical compounds classified as such in C07C is classified in A61P to the extent deemed useful for search.”
C07C subclass	Informative References		<u>Insert</u> the following <u>new</u> row in the Informative references table: Therapeutic activity A61P
C07D subclass	Relationships with other classification places	Multiple classification: Biocidal, pest attractant, or plant growth regulatory activity of chemical compounds or preparations is further classified in subclass A01P (this subclass does only exist in IPC). Therapeutic activity of chemical compounds is further classified in subclass A61P (this subclass does only exist in IPC). Uses of cosmetics or similar toilet preparations are further classified in subclass A61Q.	<u>Delete</u> the <u>second</u> occurrence (immediately following “subclass A61P”) of the following text: (this subclass does only exist in IPC)

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

C07D subclass	Informative references	Therapeutic activity A61P (IPC)	<u>Delete the following text after the symbol:</u> (IPC)
C07H subclass	Relationships with other classification places	MULTIPLE CLASSIFICATION table: Therapeutic activity of chemical compounds A61P (IPC)	<u>Delete the following text after the symbol:</u> (IPC)
C07H subclass	Special rules of classification (7 th paragraph and table (2 nd row)):	Therapeutic activity of chemical compounds A61P (IPC)	<u>Delete the following text after the symbol:</u> (IPC)
C07J subclass	Informative references		<u>Insert the following new row in the Informative references table:</u> Therapeutic activity A61P

NOTES:

- The table above is used for corrections or modifications to existing definitions, e.g. delete an entire definition or part thereof; propose new wording or modify wording of a section, change the symbol the definition is associated with, change or delete a reference symbol, etc.
- Do not delete (F) symbol definitions.

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61P 1/00	A61P 1/00	New
A61P 1/02	A61P 1/02	New
A61P 1/04	A61P 1/04	New
A61P 1/06	A61P 1/06	New
A61P 1/08	A61P 1/08	New
A61P 1/10	A61P 1/10	New
A61P 1/12	A61P 1/12	New
A61P 1/14	A61P 1/14	New
A61P 1/16	A61P 1/16	New
A61P 1/18	A61P 1/18	New
A61P 3/00	A61P 3/00	New
A61P 3/02	A61P 3/02	New
A61P 3/04	A61P 3/04	New
A61P 3/06	A61P 3/06	New
A61P 3/08	A61P 3/08	New
A61P 3/10	A61P 3/10	New
A61P 3/12	A61P 3/12	New
A61P 3/14	A61P 3/14	New
A61P 5/00	A61P 5/00	New
A61P 5/02	A61P 5/02	New
A61P 5/04	A61P 5/04	New
A61P 5/06	A61P 5/06	New
A61P 5/08	A61P 5/08	New
A61P 5/10	A61P 5/10	New
A61P 5/12	A61P 5/12	New
A61P 5/14	A61P 5/14	New
A61P 5/16	A61P 5/16	New
A61P 5/18	A61P 5/18	New
A61P 5/20	A61P 5/20	New
A61P 5/22	A61P 5/22	New
A61P 5/24	A61P 5/24	New
A61P 5/26	A61P 5/26	New
A61P 5/28	A61P 5/28	New
A61P 5/30	A61P 5/30	New
A61P 5/32	A61P 5/32	New
A61P 5/34	A61P 5/34	New
A61P 5/36	A61P 5/36	New
A61P 5/38	A61P 5/38	New

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61P 5/40	A61P 5/40	New
A61P 5/42	A61P 5/42	New
A61P 5/44	A61P 5/44	New
A61P 5/46	A61P 5/46	New
A61P 5/48	A61P 5/48	New
A61P 5/50	A61P 5/50	New
A61P 7/00	A61P 7/00	New
A61P 7/02	A61P 7/02	New
A61P 7/04	A61P 7/04	New
A61P 7/06	A61P 7/06	New
A61P 7/08	A61P 7/08	New
A61P 7/10	A61P 7/10	New
A61P 7/12	A61P 7/12	New
A61P 9/00	A61P 9/00	New
A61P 9/02	A61P 9/02	New
A61P 9/04	A61P 9/04	New
A61P 9/06	A61P 9/06	New
A61P 9/08	A61P 9/08	New
A61P 9/10	A61P 9/10	New
A61P 9/12	A61P 9/12	New
A61P 9/14	A61P 9/14	New
A61P 11/00	A61P 11/00	New
A61P 11/02	A61P 11/02	New
A61P 11/04	A61P 11/04	New
A61P 11/06	A61P 11/06	New
A61P 11/08	A61P 11/08	New
A61P 11/10	A61P 11/10	New
A61P 11/12	A61P 11/12	New
A61P 11/14	A61P 11/14	New
A61P 11/16	A61P 11/16	New
A61P 13/00	A61P 13/00	New
A61P 13/02	A61P 13/02	New
A61P 13/04	A61P 13/04	New
A61P 13/06	A61P 13/06	New
A61P 13/08	A61P 13/08	New
A61P 13/10	A61P 13/10	New
A61P 13/12	A61P 13/12	New
A61P 15/00	A61P 15/00	New
A61P 15/02	A61P 15/02	New

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61P 15/04	A61P 15/04	New
A61P 15/06	A61P 15/06	New
A61P 15/08	A61P 15/08	New
A61P 15/10	A61P 15/10	New
A61P 15/12	A61P 15/12	New
A61P 15/14	A61P 15/14	New
A61P 15/16	A61P 15/16	New
A61P 15/18	A61P 15/18	New
A61P 17/00	A61P 17/00	New
A61P 17/02	A61P 17/02	New
A61P 17/04	A61P 17/04	New
A61P 17/06	A61P 17/06	New
A61P 17/08	A61P 17/08	New
A61P 17/10	A61P 17/10	New
A61P 17/12	A61P 17/12	New
A61P 17/14	A61P 17/14	New
A61P 17/16	A61P 17/16	New
A61P 17/18	A61P 17/18	New
A61P 19/00	A61P 19/00	New
A61P 19/02	A61P 19/02	New
A61P 19/04	A61P 19/04	New
A61P 19/06	A61P 19/06	New
A61P 19/08	A61P 19/08	New
A61P 19/10	A61P 19/10	New
A61P 21/00	A61P 21/00	New
A61P 21/02	A61P 21/02	New
A61P 21/04	A61P 21/04	New
A61P 21/06	A61P 21/06	New
A61P 23/00	A61P 23/00	New
A61P 23/02	A61P 23/02	New
A61P 25/00	A61P 25/00	New
A61P 25/02	A61P 25/02	New
A61P 25/04	A61P 25/04	New
A61P 25/06	A61P 25/06	New
A61P 25/08	A61P 25/08	New
A61P 25/10	A61P 25/10	New
A61P 25/12	A61P 25/12	New
A61P 25/14	A61P 25/14	New
A61P 25/16	A61P 25/16	New

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61P 25/18	A61P 25/18	New
A61P 25/20	A61P 25/20	New
A61P 25/22	A61P 25/22	New
A61P 25/24	A61P 25/24	New
A61P 25/26	A61P 25/26	New
A61P 25/28	A61P 25/28	New
A61P 25/30	A61P 25/30	New
A61P 25/32	A61P 25/32	New
A61P 25/34	A61P 25/34	New
A61P 25/36	A61P 25/36	New
A61P 27/00	A61P 27/00	New
A61P 27/02	A61P 27/02	New
A61P 27/04	A61P 27/04	New
A61P 27/06	A61P 27/06	New
A61P 27/08	A61P 27/08	New
A61P 27/10	A61P 27/10	New
A61P 27/12	A61P 27/12	New
A61P 27/14	A61P 27/14	New
A61P 27/16	A61P 27/16	New
A61P 29/00	A61P 29/00	New
A61P 29/02	A61P 29/02	New
A61P 31/00	A61P 31/00	New
A61P 31/02	A61P 31/02	New
A61P 31/04	A61P 31/04	New
A61P 31/06	A61P 31/06	New
A61P 31/08	A61P 31/08	New
A61P 31/10	A61P 31/10	New
A61P 31/12	A61P 31/12	New
A61P 31/14	A61P 31/14	New
A61P 31/16	A61P 31/16	New
A61P 31/18	A61P 31/18	New
A61P 31/20	A61P 31/20	New
A61P 31/22	A61P 31/22	New
A61P 33/00	A61P 33/00	New
A61P 33/02	A61P 33/02	New
A61P 33/04	A61P 33/04	New
A61P 33/06	A61P 33/06	New
A61P 33/08	A61P 33/08	New
A61P 33/10	A61P 33/10	New
A61P 33/12	A61P 33/12	New

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61P 33/14	A61P 33/14	New
A61P 35/00	A61P 35/00	New
A61P 35/02	A61P 35/02	New
A61P 35/04	A61P 35/04	New
A61P 37/00	A61P 37/00	New
A61P 37/02	A61P 37/02	New
A61P 37/04	A61P 37/04	New
A61P 37/06	A61P 37/06	New
A61P 37/08	A61P 37/08	New
A61P 39/00	A61P 39/00	New
A61P 39/02	A61P 39/02	New
A61P 39/04	A61P 39/04	New
A61P 39/06	A61P 39/06	New
A61P 41/00	A61P 41/00	New
A61P 43/00	A61P 43/00	New

*Action column:

- For an (N) or (Q) entry, provide an IPC symbol and complete the Action column with “NEW.”
- For an existing CPC main trunk entry or indexing entry where the existing IPC symbol needs to be changed, provide an updated IPC symbol and complete the Action column with “UPDATED.”
- For a (D) CPC entry or indexing entry complete the Action column with “DELETE.” IPC symbol does not need to be included in the IPC column.
- For an (N) 2000 series CPC entry which is positioned within the main trunk scheme (breakdown code) provide an IPC symbol and complete the action column with “NEW”.
- For an (N) 2000 series CPC entry positioned at the end of the CPC scheme (orthogonal code), with no IPC equivalent, complete the IPC column with “CPCONLY” and complete the action column with “NEW”.

NOTES:

- F symbols are not included in the CICL table above.
- E and M symbols are not included in the CICL table above unless a change to the existing IPC is desired.

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

5. CROSS-REFERENCE LIST (CRL)

Definitions references impacted by this revision project

<u>Location of reference to be changed</u>	<u>Referenced subclass or group to be changed</u>	<u>Section of definition</u>	<u>Action; New reference symbol; New text</u>
A61N	A61P	Informative references	<u>Replace</u> text with: Specific therapeutic activity of chemical compounds or medicinal preparations
A61Q	A61P 17/00	Informative references	<u>Replace</u> text with: Drugs for dermatological disorders
A61Q 17/00	A61P 17/02	Informative references	<u>Replace</u> text with: for treating wounds, ulcers, burns, scars, keloids, or the like
C01B	A61P	Relationships with other classification places	<u>Replace</u> “Therapeutic activity of chemical compounds or medicinal preparations is further classified in subclass A61P.” under “Multiple Classification” with the following: Therapeutic activity of chemical compounds or medicinal preparations is further classified in subclass A61P (as secondary classification).
C07J	A61P	Relationships with other classification places	<u>Replace</u> “Therapeutic activity of compounds is further classified in subclass A61P.” under “Multiple Classification” with the following: Therapeutic activity of chemical compounds or medicinal preparations is further classified in subclass A61P (as secondary classification).

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>Location of reference to be changed</u>	<u>Referenced subclass or group to be changed</u>	<u>Section of definition</u>	<u>Action; New reference symbol; New text</u>
C08F	A61P	Relationships with other classification places	<p><u>Replace</u> “Therapeutic activity of compounds is further classified in subclass A61P.” under “Multiple Classification”</p> <p>with the following:</p> <p>Therapeutic activity of chemical compounds or medicinal preparations is further classified in subclass A61P (as secondary classification).</p>
C08G	A61P	Relationships with other classification places	<p><u>Replace</u> “Therapeutic activity of macromolecular compounds is further classified in subclass A61P.” under “Multiple Classification”</p> <p>with the following:</p> <p>Therapeutic activity of macromolecular compounds is further classified in subclass A61P (as secondary classification).</p>
C08H	A61P	Relationships with other classification places	<p><u>Replace</u> “Therapeutic activity of compounds is further classified in subclass A61P.” under “Multiple Classification”</p> <p>with the following:</p> <p>Therapeutic activity of chemical compounds or medicinal preparations is further classified in subclass A61P (as secondary classification).</p>

CPC NOTICE OF CHANGES 453

DATE: JANUARY 1, 2018

PROJECT RP0329

<u>Location of reference to be changed</u>	<u>Referenced subclass or group to be changed</u>	<u>Section of definition</u>	<u>Action; New reference symbol; New text</u>
C08L	A61P	Relationships with other classification places	<p><u>Replace</u> “Therapeutic activity of macromolecular compounds is further classified in subclass A61P.” under “Multiple Classification”</p> <p>with the following:</p> <p>Therapeutic activity of macromolecular compounds is further classified in subclass A61P (as secondary classification).</p>
C12N	A61P	Relationships with other classification places	<p><u>Replace</u> “Therapeutic activity of compounds containing microorganisms, single cell proteins, or enzymes, is further classified in subclass A61P.” under “Multiple Classification”</p> <p>with the following:</p> <p>Therapeutic activity of compounds containing microorganisms, single cell proteins, or enzymes, is further classified in subclass A61P (as secondary classification).</p>

NOTES:

- The CRL tables above are used for changes to locations **outside** of the project scope. Changes to references in scheme titles or definitions **inside** the project scope will be reflected in the “scheme change” template or one of the “definition” templates.
- In addition to other changes proposed in the tables above, in the column titled “Referenced subclass or group to be changed,” **referenced** D symbols should indicate an action of “delete” or should indicate a replacement symbol and **referenced** F symbols should indicate a replacement symbol.
- When a reference is deleted, text related to that reference will also be deleted unless other references or a range of references associated with the same text remain.